{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:56:32Z","timestamp":1777564592339,"version":"3.51.4"},"reference-count":31,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["848016004"],"award-info":[{"award-number":["848016004"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jval.2025.07.018","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T21:43:55Z","timestamp":1754430235000},"page":"1714-1721","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Genotype-Specific Tricyclic Antidepressant Dosing in Patients With Major Depressive Disorder: A Trial-Based Economic Evaluation"],"prefix":"10.1016","volume":"28","author":[{"given":"Sophie E.","family":"ter Hark","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wietske","family":"Kievit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerjon","family":"Hannink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cornelis F.","family":"Vos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Spijker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annemarie","family":"van der Meij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne J.","family":"Grotenhuis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raluca","family":"Mihaescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rogier","family":"Donders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rob E.","family":"Aarnoutse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnt F.A.","family":"Schellekens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marieke J.H.","family":"Coenen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joost G.E.","family":"Janzing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jval.2025.07.018_bib1","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/wps.21087","article-title":"Prevalence and trends of common mental disorders from 2007-2009 to 2019-2022: results from the Netherlands Mental Health Survey and Incidence Studies (NEMESIS), including comparison of prevalence rates before vs. during the COVID-19 pandemic","volume":"22","author":"Ten Have","year":"2023","journal-title":"World Psychiatry"},{"issue":"9","key":"10.1016\/j.jval.2025.07.018_bib3","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1176\/ajp.2006.163.9.1561","article-title":"Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers","volume":"163","author":"Kessler","year":"2006","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jval.2025.07.018_bib4","author":"de Graaf"},{"issue":"5","key":"10.1016\/j.jval.2025.07.018_bib5","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/fampra\/cmq033","article-title":"Health care costs of depression in primary care patients in the Netherlands","volume":"27","author":"Bosmans","year":"2010","journal-title":"Fam Pract"},{"issue":"1","key":"10.1016\/j.jval.2025.07.018_bib7","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1186\/s12888-021-03490-x","article-title":"Tricyclic antidepressants for major depressive disorder: a comprehensive evaluation of current practice in the Netherlands","volume":"21","author":"Vos","year":"2021","journal-title":"BMC Psychiatry"},{"issue":"1","key":"10.1016\/j.jval.2025.07.018_bib8","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2217\/pgs-2018-0142","article-title":"Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials","volume":"20","author":"Bousman","year":"2019","journal-title":"Pharmacogenomics"},{"issue":"6","key":"10.1016\/j.jval.2025.07.018_bib9","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/cpt.2748","article-title":"Pharmacogenomic testing and depressive symptom remission: a systematic review and meta-analysis of prospective, controlled clinical trials","volume":"112","author":"Brown","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jval.2025.07.018_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2022.104965","article-title":"Effectiveness of pharmacogenomic tests including CYP2D6 and CYP2C19 genomic variants for guiding the treatment of depressive disorders: systematic review and meta-analysis of randomised controlled trials","volume":"144","author":"Arnone","year":"2023","journal-title":"Neurosci Biobehav Rev"},{"issue":"4","key":"10.1016\/j.jval.2025.07.018_bib11","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41397-021-00249-1","article-title":"Economic evaluation in psychiatric pharmacogenomics: a systematic review","volume":"21","author":"Karamperis","year":"2021","journal-title":"Pharmacogenomics J"},{"issue":"6","key":"10.1016\/j.jval.2025.07.018_bib12","doi-asserted-by":"crossref","first-page":"720","DOI":"10.4088\/JCP.15r10583","article-title":"Does pharmacogenomic testing improve clinical outcomes for major depressive disorder? A systematic review of clinical trials and cost-effectiveness studies","volume":"78","author":"Rosenblat","year":"2017","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"10.1016\/j.jval.2025.07.018_bib13","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/sj.bjp.0707253","article-title":"Tricyclic antidepressant pharmacology and therapeutic drug interactions updated","volume":"151","author":"Gillman","year":"2007","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jval.2025.07.018_bib14","series-title":"Pharmacogenomic Recommendations - Tricyclic Antidepressants","year":"2022"},{"issue":"1","key":"10.1016\/j.jval.2025.07.018_bib15","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/cpt.597","article-title":"Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update","volume":"102","author":"Hicks","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.jval.2025.07.018_bib16","first-page":"312","article-title":"Farmacogenetica in de psychiatrie; de huidige status quo. Article in Dutch","volume":"64","author":"van Westrhenen","year":"2022","journal-title":"Tijdschr Psychiatr"},{"issue":"5","key":"10.1016\/j.jval.2025.07.018_bib17","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.12443","article-title":"Effectiveness of genotype-specific tricyclic antidepressant dosing in patients with major depressive disorder: a randomized clinical trial","volume":"6","author":"Vos","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"9","key":"10.1016\/j.jval.2025.07.018_bib18","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s40261-022-01182-2","article-title":"Cost-utility analysis of pharmacogenetic testing based on CYP2C19 or CYP2D6 in major depressive disorder: assessing the drivers of different cost-effectiveness levels from an Italian societal perspective","volume":"42","author":"Carta","year":"2022","journal-title":"Clin Drug Investig"},{"issue":"5","key":"10.1016\/j.jval.2025.07.018_bib19","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41397-019-0070-8","article-title":"An economic model of the cost-utility of pre-emptive genetic testing to support pharmacotherapy in patients with major depression in primary care","volume":"19","author":"Sluiter","year":"2019","journal-title":"Pharmacogenomics J"},{"issue":"12","key":"10.1016\/j.jval.2025.07.018_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0169065","article-title":"A model based cost-effectiveness analysis of routine genotyping for CYP2D6 among older, depressed inpatients starting nortriptyline pharmacotherapy","volume":"11","author":"Berm","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.jval.2025.07.018_bib21","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.cpm.2023.07.006","article-title":"A primer on cost-effectiveness analysis","volume":"41","author":"Albright","year":"2024","journal-title":"Clin Podiatr Med Surg"},{"issue":"1","key":"10.1016\/j.jval.2025.07.018_bib22","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"10.1016\/j.jval.2025.07.018_bib23","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00131746-200603000-00002","article-title":"Self-rated global measure of the frequency, intensity, and burden of side effects","volume":"12","author":"Wisniewski","year":"2006","journal-title":"J Psychiatr Pract"},{"issue":"6","key":"10.1016\/j.jval.2025.07.018_bib29","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.jval.2015.05.009","article-title":"The iMTA productivity cost questionnaire: a standardized instrument for measuring and valuing health-related productivity losses","volume":"18","author":"Bouwmans","year":"2015","journal-title":"Value Health"},{"issue":"11","key":"10.1016\/j.jval.2025.07.018_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0187477","article-title":"Update of the Dutch manual for costing studies in health care","volume":"12","author":"Kanters","year":"2017","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.jval.2025.07.018_bib31","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"issue":"4","key":"10.1016\/j.jval.2025.07.018_bib32","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.jval.2016.01.003","article-title":"Dutch tariff for the five-level version of EQ-5D","volume":"19","author":"Versteegh","year":"2016","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.jval.2025.07.018_bib33","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/sim.7956","article-title":"Combining multiple imputation and bootstrap in the analysis of cost-effectiveness trial data","volume":"38","author":"Brand","year":"2019","journal-title":"Stat Med"},{"issue":"1","key":"10.1016\/j.jval.2025.07.018_bib34","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1186\/s12913-021-06513-1","article-title":"The statistical approach in trial-based economic evaluations matters: get your statistics together","volume":"21","author":"Mutubuki","year":"2021","journal-title":"BMC Health Serv Res"},{"issue":"5","key":"10.1016\/j.jval.2025.07.018_bib35","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1111\/j.1523-1755.2004.00950.x","article-title":"Acceptance and rejection: cost-effectiveness and the working nephrologist","volume":"66","author":"McFarlane","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.jval.2025.07.018_bib36","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jpsychires.2017.07.024","article-title":"Prognostic factors for return to work after depression-related work disability: a systematic review and meta-analysis","volume":"95","author":"Ervasti","year":"2017","journal-title":"J Psychiatr Res"},{"issue":"7","key":"10.1016\/j.jval.2025.07.018_bib37","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1093\/ecco-jcc\/jjz009","article-title":"Genotype-guided thiopurine dosing does not lead to additional costs in patients with inflammatory bowel disease","volume":"13","author":"Sluiter","year":"2019","journal-title":"J Crohns Colitis"},{"issue":"44","key":"10.1016\/j.jval.2025.07.018_bib38","doi-asserted-by":"crossref","first-page":"E1499","DOI":"10.1503\/cmaj.221785","article-title":"Cost-effectiveness of pharmacogenomic-guided treatment for major depression","volume":"195","author":"Ghanbarian","year":"2023","journal-title":"CMAJ"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301525024854?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301525024854?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T10:49:20Z","timestamp":1762339760000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301525024854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1098301525024854"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2025.07.018","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genotype-Specific Tricyclic Antidepressant Dosing in Patients With Major Depressive Disorder: A Trial-Based Economic Evaluation","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2025.07.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}